Oncolytics Biotech (TSX:ONC) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ONC Overzicht aandelen

Oncolytics Biotech Inc, een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken en ontwikkelen van farmaceutische producten voor de behandeling van kanker.

Over het bedrijf

ONC fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 98% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 68.41% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( CA$0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( CA$92M )

Oncolytics Biotech Inc. Concurrenten

Covalon Technologies

TSXV:COV

CA$91.2m

Eupraxia Pharmaceuticals

TSX:EPRX

CA$125.7m

Medicenna Therapeutics

TSX:MDNA

CA$157.7m

Satellos Bioscience

TSX:MSCL

CA$56.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Oncolytics Biotech
Historische aandelenkoersen
Huidige aandelenkoers	CA$1.49
52 Week Hoogtepunt	CA$2.81
52 Week Laag	CA$1.15
Bèta	1.35
11 maand verandering	7.97%
3 maanden verandering	6.43%
1 Jaar Verandering	-46.60%
33 jaar verandering	-38.68%
5 jaar verandering	132.81%
Verandering sinds IPO	-89.54%

Recent nieuws en updates

Recent updates

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31

Rendement voor aandeelhouders

	ONC	CA Biotechs	CA Markt
7D	24.2%	3.7%	-0.3%
1Y	-46.6%	-38.8%	23.4%

Rendement versus industrie: ONC presteerde slechter dan de Canadian Biotechs -sector, die het afgelopen jaar een rendement van -43.8 % opleverde.

Rendement versus markt: ONC presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 24.6 % opleverde.

Prijsvolatiliteit

Is ONC's price volatile compared to industry and market?
ONC volatility
ONC Average Weekly Movement	7.4%
Biotechs Industry Average Movement	8.9%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.2%
10% least volatile stocks in CA Market	3.1%

Stabiele aandelenkoers: ONC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van ONC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	29	Wayne Pisano	www.oncolyticsbiotech.com

Oncolytics Biotech Inc, een biofarmaceutisch bedrijf in een klinische fase, richt zich op het ontdekken en ontwikkelen van farmaceutische producten voor de behandeling van kanker. Het bedrijf ontwikkelt pelareorep, een intraveneus toegediend immunotherapeutisch middel, dat zich in fase 3 van de klinische studie bevindt voor de behandeling van hormoonreceptor-positieve / humane epidermale groeifactor 2-negatieve gemetastaseerde borstkanker en gevorderd/gemetastaseerd pancreas ductaal adenocarcinoom. Het heeft een overeenkomst voor gezamenlijke ontwikkeling met Merck KGaA en Pfizer Inc. voor de gezamenlijke ontwikkeling van pelareorep, evenals met Roche Holding AG.

Oncolytics Biotech Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Oncolytics Biotech zich tot de beurswaarde?
ONC fundamentele statistieken
Marktkapitalisatie	CA$97.84m
Inkomsten(TTM)	-CA$28.02m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-4.1x

Koers/Winstverhouding

Is ONC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ONC resultatenrekening (TTM)
Inkomsten	CA$0
Kosten van inkomsten	CA$0
Brutowinst	CA$0
Overige uitgaven	CA$28.02m
Inkomsten	-CA$28.02m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.36
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ONC op de lange termijn?

Bekijk historische prestaties en vergelijking

ONC Overzicht aandelen

Beloningen

Risicoanalyse

Oncolytics Biotech Inc. Concurrenten

TSXV:COV

CA$91.2m

TSX:EPRX

CA$125.7m

TSX:MDNA

CA$157.7m

TSX:MSCL

CA$56.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Recent updates

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Price target decreased by 23% to CA$5.83

New minor risk - Profitability

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Oncolytics Biotech Inc. Announces Selection of Pelareorep for Inclusion as New Investigational Treatment in Precision Promise, an Innovative Adaptive Phase 3 Clinical Trial

New minor risk - Market cap size

Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS

Consensus EPS estimates upgraded to CA$0.43 loss

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 20%

Price target decreased by 14% to CA$6.50

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting

Price target decreased to CA$6.21

Oncolytics Biotech(R) Appoints Jonathan Rigby to Its Board of Directors

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Oncolytics Biotech Inc. Appoints James T. Parsons to its Board of Directors

Independent Director recently bought CA$56k worth of stock

Consensus forecasts updated

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Oncolytics Biotech Inc. Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with Chimeric Antigen Receptor T Cell Therapy in Solid Tumors

Oncolytics Biotech Inc. Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Oncolytics Biotech Inc., Annual General Meeting, Jun 16, 2022

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of Its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech Inc. Promotes Thomas C. Heineman to Chief Medical Officer

No longer forecast to breakeven

Oncolytics Biotech® Inc. Provides Positive Safety Update on Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Oncolytics Biotech® Inc. Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Oncolytics Biotech Inc. Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

No longer forecast to breakeven

Oncolytics Biotech Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

No longer forecast to breakeven

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-Of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Oncolytics Biotech Inc., Annual General Meeting, May 07, 2021

Oncolytics Biotech Inc. Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Price target raised to CA$10.13